Literature DB >> 10169665

The use of consensus methods and expert panels in pharmacoeconomic studies. Practical applications and methodological shortcomings.

C Evans1.   

Abstract

The use of expert opinion in pharmacoeconomic studies is widespread. A review of the relevant literature has shown that expert opinion is frequently used in decision analysis, Markov models and disease management, with estimates of potential values derived from Delphi panels, modified Delphi panels and expert round tables. These consensus-gathering methods are often applied as if potential drawbacks to their application were absent. This article reviews and summarises the use of these techniques in pharmacoeconomic research and evaluates the potential shortcomings of the methodology employed. In particular, several areas of concern are noted: the provision of baseline information or seed algorithms to panellists, the high attrition rate of panels, the criteria for selecting experts and the definition of consensus. This article offers recommendations for the future application of these techniques and concludes that expert opinion can still play a valuable role in pharmacoeconomic research.

Mesh:

Year:  1997        PMID: 10169665     DOI: 10.2165/00019053-199712020-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  39 in total

1.  Panellist consistency in the assessment of medical appropriateness.

Authors:  J McDonnell; A Meijler; J P Kahan; S J Bernstein; H Rigter
Journal:  Health Policy       Date:  1996-09       Impact factor: 2.980

2.  Cost effectiveness of antiviral treatment with zalcitabine plus zidovudine for AIDS patients with CD4+ counts less than 300/microliters in 5 European countries.

Authors:  K Simpson; E J Hatziandreu; F Andersson; A Shakespeare; I Oleksy; A N Tosteson
Journal:  Pharmacoeconomics       Date:  1994-12       Impact factor: 4.981

3.  Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin.

Authors:  E J Hatziandreu; R E Brown; D A Revicki; R Turner; J Martindale; S Levine; J E Siegel
Journal:  Pharmacoeconomics       Date:  1994-03       Impact factor: 4.981

4.  A cost-effectiveness comparison of the use of antimicrobial agents for treatment or prophylaxis of travelers' diarrhea.

Authors:  R R Reves; P C Johnson; C D Ericsson; H L DuPont
Journal:  Arch Intern Med       Date:  1988-11

5.  A Markov process analysis comparing the cost effectiveness of maintenance therapy with citalopram versus standard therapy in major depression.

Authors:  M J Nuijten; M Hardens; E Souêtre
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

6.  The Delphi methodology (Part one): A useful administrative approach.

Authors:  N Jairath; J Weinstein
Journal:  Can J Nurs Adm       Date:  1994 Sep-Oct

7.  Is consensus reproducible? A study of an algorithmic guidelines development process.

Authors:  S D Pearson; C Z Margolis; S Davis; L K Schreier; H N Sokol; L K Gottlieb
Journal:  Med Care       Date:  1995-06       Impact factor: 2.983

8.  Cost-effectiveness of Helicobacter pylori eradication for the long-term management of duodenal ulcer in Canada.

Authors:  B O'Brien; R Goeree; A H Mohamed; R Hunt
Journal:  Arch Intern Med       Date:  1995-10-09

9.  Agreement on disease-specific criteria for do-not-resuscitate orders in acute stroke. Members of the Canadian and Western New York Stroke Consortiums.

Authors:  A V Alexandrov; P M Pullicino; E M Meslin; J W Norris
Journal:  Stroke       Date:  1996-02       Impact factor: 7.914

10.  A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis.

Authors:  B S Bloom; A L Hillman; A M Fendrick; J S Schwartz
Journal:  Ann Intern Med       Date:  1993-02-15       Impact factor: 25.391

View more
  29 in total

1.  Expert judgement in pharmacoeconomic studies. Guidance and future use.

Authors:  C Evans; B Crawford
Journal:  Pharmacoeconomics       Date:  2000-06       Impact factor: 4.981

Review 2.  The selection of data sources for use in modelling studies.

Authors:  M J Nuijten
Journal:  Pharmacoeconomics       Date:  1998-03       Impact factor: 4.981

3.  Validation of expert opinion in identifying comorbidities associated with atopic dermatitis/eczema.

Authors:  Charles N Ellis; Lynn A Drake; Mary M Prendergast; William Abramovits; Mark Boguniewicz; C Ralph Daniel; Mark Lebwohl; Seth R Stevens; Diane L Whitaker-Worth; Kuo B Tong
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

4.  Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium.

Authors:  Prateek Sharma; David A Katzka; Neil Gupta; Jaffer Ajani; Navtej Buttar; Amitabh Chak; Douglas Corley; Hashem El-Serag; Gary W Falk; Rebecca Fitzgerald; John Goldblum; Frank Gress; David H Ilson; John M Inadomi; Ernest J Kuipers; John P Lynch; Frank McKeon; David Metz; Pankaj J Pasricha; Oliver Pech; Richard Peek; Jeffrey H Peters; Alessandro Repici; Stefan Seewald; Nicholas J Shaheen; Rhonda F Souza; Stuart J Spechler; Prashanth Vennalaganti; Kenneth Wang
Journal:  Gastroenterology       Date:  2015-08-19       Impact factor: 22.682

Review 5.  Tools for Assessing Potential Significance of Pharmacist Interventions: A Systematic Review.

Authors:  Thi-Ha Vo; Bruno Charpiat; Claire Catoire; Michel Juste; Renaud Roubille; François-Xavier Rose; Sébastien Chanoine; Jean-Luc Bosson; Ornella Conort; Benoît Allenet; Pierrick Bedouch
Journal:  Drug Saf       Date:  2016-02       Impact factor: 5.606

6.  Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process.

Authors:  Cathy Bennett; Nimish Vakil; Jacques Bergman; Rebecca Harrison; Robert Odze; Michael Vieth; Scott Sanders; Laura Gay; Oliver Pech; Gaius Longcroft-Wheaton; Yvonne Romero; John Inadomi; Jan Tack; Douglas A Corley; Hendrik Manner; Susi Green; David Al Dulaimi; Haythem Ali; Bill Allum; Mark Anderson; Howard Curtis; Gary Falk; M Brian Fennerty; Grant Fullarton; Kausilia Krishnadath; Stephen J Meltzer; David Armstrong; Robert Ganz; Gianpaolo Cengia; James J Going; John Goldblum; Charles Gordon; Heike Grabsch; Chris Haigh; Michio Hongo; David Johnston; Ricky Forbes-Young; Elaine Kay; Philip Kaye; Toni Lerut; Laurence B Lovat; Lars Lundell; Philip Mairs; Tadakuza Shimoda; Stuart Spechler; Stephen Sontag; Peter Malfertheiner; Iain Murray; Manoj Nanji; David Poller; Krish Ragunath; Jaroslaw Regula; Renzo Cestari; Neil Shepherd; Rajvinder Singh; Hubert J Stein; Nicholas J Talley; Jean-Paul Galmiche; Tony C K Tham; Peter Watson; Lisa Yerian; Massimo Rugge; Thomas W Rice; John Hart; Stuart Gittens; David Hewin; Juergen Hochberger; Peter Kahrilas; Sean Preston; Richard Sampliner; Prateek Sharma; Robert Stuart; Kenneth Wang; Irving Waxman; Chris Abley; Duncan Loft; Ian Penman; Nicholas J Shaheen; Amitabh Chak; Gareth Davies; Lorna Dunn; Yngve Falck-Ytter; John Decaestecker; Pradeep Bhandari; Christian Ell; S Michael Griffin; Stephen Attwood; Hugh Barr; John Allen; Mark K Ferguson; Paul Moayyedi; Janusz A Z Jankowski
Journal:  Gastroenterology       Date:  2012-04-24       Impact factor: 22.682

7.  Economic evaluation of intravenous itraconazole for presumed systemic fungal infections in neutropenic patients in Korea.

Authors:  K Moeremans; L Annemans; Ji-So Ryu; Kang-Won Choe; Wan-Shik Shine
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

8.  Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany.

Authors:  P K Schädlich; J G Brecht
Journal:  Pharmacoeconomics       Date:  2000-01       Impact factor: 4.981

Review 9.  A Delphi consensus panel on nutritional therapy in chronic kidney disease.

Authors:  Vincenzo Bellizzi; Stefano Bianchi; Piergiorgio Bolasco; Giuliano Brunori; Adamasco Cupisti; Giovanni Gambaro; Loreto Gesualdo; Pasquale Polito; Domenico Santoro; Antonio Santoro
Journal:  J Nephrol       Date:  2016-06-20       Impact factor: 3.902

10.  Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance.

Authors:  P K Schädlich; J G Brecht; M Brunetti; E Pagano; B Rangoonwala; E Huppertz
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.